These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30276829)

  • 21. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major.
    Ponti ML; Comitini F; Murgia D; Ganga R; Canu R; Dessì C; Foschini ML; Leoni G; Morittu M; Perra M; Pilia MP; Casini MR; Zappu A; Origa R
    Dig Liver Dis; 2019 Apr; 51(4):561-567. PubMed ID: 30658940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response.
    Sacks HS
    Ann Intern Med; 2017 Jul; 167(2):JC3. PubMed ID: 28715825
    [No Abstract]   [Full Text] [Related]  

  • 23. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
    Khaliq S; Raza SM
    Medicina (Kaunas); 2018 Nov; 54(5):. PubMed ID: 30400604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.
    Chhatwal J; Chen Q; Ayer T; Bethea ED; Kanwal F; Kowdley KV; Wang X; Roberts MS; Gordon SC
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1023-1031. PubMed ID: 29377245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.
    Klag T; Dietz J; Werner CR; Schwarz JM; Lauer UM; Beck R; Malek NP; Sarrazin C; Berg CP
    J Hepatol; 2017 Apr; 66(4):862-863. PubMed ID: 28082147
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
    Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
    PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
    Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
    Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.
    Trabut JB; Barrault C; Charlot H; Carmona D; Bourdel A; Benslimane M; François M; Kini-Matondo W; Causse R; Roudot-Thoraval F; Hézode C
    J Addict Med; 2018; 12(5):346-352. PubMed ID: 29702515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Cacoub P; Desbois AC; Comarmond C; Saadoun D
    Gut; 2018 Nov; 67(11):2025-2034. PubMed ID: 29703790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
    Falcão F; Lopes C; Viegas E; Perez R; Aldir I; Farinha H; Carvalho A; Mirco A; Marques S; Bana E Costa T; Miranda AC; Lebre L; Peixe P; Chagas C; Mansinho K; Correia JM
    Acta Med Port; 2019 Mar; 32(3):189-194. PubMed ID: 30946789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hepatitis C: Results in real life.
    Hézode C
    Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
    Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
    World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
    Fathi H; Clark A; Hill NR; Dusheiko G
    BMC Infect Dis; 2017 Nov; 17(1):722. PubMed ID: 29145802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
    J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
    Carvalho JR; Velosa J; Serejo F
    Scand J Gastroenterol; 2018; 53(7):857-863. PubMed ID: 29779403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.